Raymond James on Mirum Pharmaceuticals (MIRM): 'we think its ~$1B+ estimate for the Livmarli opportunity is continuing to look more and more conservative'

October 12, 2026 10:43 AM

Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating and $183.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found